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Abstract Over the past decade, protein kinase B (PKB, also
termed Akt) has emerged as an important signaling mediator
between extracellular cues and modulation of gene expression,
metabolism, and cell survival. The enzyme is tightly controlled
and consequences of its deregulation include loss of growth con-
trol and oncogenesis. Recent work has better characterized the
mechanism of PKB activation, including upstream regulators
and secondary binding partners. This minireview refreshes
some old concepts with new twists and highlights current out-
standing questions.
& 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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Protein kinase B (PKB, also termed Akt) is a serine/threo-
nine kinase belonging to the ‘AGC’ superfamily of protein
kinases (of which there are over 80 members). This group of
kinases shares similarity within their catalytic domain struc-
ture and in their mechanism of activation, and many are fre-
quently deregulated in human diseases including cancer. As
with other AGC kinases, PKB is regulated by upstream, sec-
ond messengers and secondary, activating enzymes. For PKB,
this activating process involves multiple inputs that strictly
control the location, duration and strength of response. The
purpose of this article is to update current understanding of
the complex PKB activation process. Interest in PKB has been
piqued by its role in promoting cell survival signals through
the phosphoinositide 3-kinase (PI3K) pathway, leading to in-
activation of a series of pro-apoptotic proteins (see Fig. 1).
The reader is directed to several recent reviews that describe
the physiological substrates and cellular functions of this cap-
tivating enzyme [1^4].
2. PKB ^ topography
In mammals, there are three isoforms of PKB (K, L, Q ;
Akt1, 2, 3). All three isoforms share a high degree of amino
acid identity and are composed of three functionally distinct
regions: an N-terminal pleckstrin homology (PH) domain, a
central catalytic domain, and a C-terminal hydrophobic motif
(HM). Together, these regions encompass a phosphoprotein
of approximately 56 kDa. This general architecture is con-
served across species including Drosophila melanogaster and
Caenorhabditis elegans, suggesting that regulation of PKB is
evolutionarily ancient. The Sch9 gene product of Saccharomy-
ces cerevisiae, although lacking a lipid binding domain, is a
likely a distant member due to similarities in its regulation.
The catalytic domain of PKB is structurally similar to other
protein kinases of the AGC family including PKA [5]. To
control the activity and speci¢city of the protein kinase do-
main, there are two important regulatory domains. The N-ter-
minal PH domain is common to numerous signaling proteins
and provides a lipid binding module to direct PKB to PI3K-
generated phosphoinositides PI(3,4,5)P3 and PI(3,4)P2. Thus,
growth factors that act to increase PI3K activity and lead to
the subsequent generation of PI(3,4,5)P3 and PI(3,4)P2 pro-
vide a plasma membrane recruitment mechanism for PKB.
Membrane recruitment of PKB is a hallmark of activation
(discussed in detail below).
The crystal structure of the PH domain of PKB bound with
the inositol head group of PI(3,4,5)P3 was recently solved [6].
Interestingly, this structure revealed di¡erences in the binding
between inositol(1,3,4,5)P4 and other PI(3,4,5)P3 binding PH
domains, including BTK and DAPP1. The most signi¢cant
of these di¡erences is that the D5 phosphate of inosi-
tol(1,3,4,5)P4 does not physically interact with the PKB PH
domain, agreeing with earlier studies demonstrating that
PI(3,4,5)P3 and PI(3,4)P2 bind to PKB with equal a⁄nities.
This has important implications regarding the upstream phos-
phatase regulators of PI3K-generated lipids, PTEN [7,8]and
SHIP [9]. Since PTEN catalyzes the dephosphorylation of
PI(3,4,5)P3 and PI(3,4)P2 at the D3 position, the actions of
this phosphatase would reduce the entire pool of lipids capa-
ble of binding with PKB. SHIP, however, catalyzes the de-
phosphorylation of PI(3,4,5)P3 to generate PI(3,4)P2. Thus,
the actions of PTEN would likely have a greater negative
impact on the activation of PKB than SHIP.
The second important regulatory domain of PKB is a C-ter-
minal HM present in many other AGC kinases [2,10]. Studies
on PKB and other AGC kinases including protein kinase C,
p70 ribosomal S6 kinase, serum and glucocorticoid-activated
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kinase (SGK) and RSK indicate that the HM provides a dual
role in regulating kinase activity. The HM provides a docking
site for the upstream activating kinase, 3-phosphoinositide-
dependent kinase-1 (PDK1) [11^13]. Interrupting this docking
interaction severely attenuates phosphorylation of the activa-
tion loop (T-loop) of AGC kinases. More recent biochemical
and structural studies have elegantly demonstrated that the
HM also serves as an allosteric regulator of catalytic activity
[5,12,14]. The HM provides stability to the catalytic core by
association with hydrophobic and phosphate binding pockets
created by a cleft formed at the junction of the KB-helix,
KC-helix and L5-sheet in the N-lobe of the kinase domain.
This pocket has been called the ‘PRK2-interacting fragment
(PIF)-pocket’ because it was initially determined to be the site
of binding for the HM fragment of a protein kinase termed
PRK2, called PIF [15]. Stabilization of the N-lobe of the ki-
nase domain by binding of the HM increases the phospho-
transfer rate by 10-fold. Similar dynamics exist for PKA and
the interactions are predicted in the crystal structure of this
kinase [16]. For both PKB and PKA, mutations of key phe-
nylalanine residues within the HM compromise catalytic ac-
tivity [17].
3. Phosphorylation in PKB regulation
PKB is activated by, and dependent upon, multisite phos-
phorylation. As introduced above, a main site of phosphory-
lation is within the activation T-loop at Thr308 (for PKBK).
Phosphorylation of PKB on Thr308, similar to other AGC
kinases, causes a charge-induced change in conformation al-
lowing substrate binding and greatly elevated rate of catalysis.
Some of the AGC kinases are constitutively phosphorylated
on the equivalent activation loop residue and regulation of
activity is provided through other means, such as allosteric
e¡ectors or release from pseudosubstrate inhibitory domains.
However, PKB is one example of the AGC kinases for which
there is very low activation loop phosphorylation in resting
cells and rapid increase in phosphorylation upon agonist stim-
ulation. The phosphorylation of Thr308 strictly governs the
activation of PKB, and its mutation to non-phosphorylatable
alanine greatly reduces activity [18].
There is convincing evidence that Thr308 is phosphorylated
by the PDK1 [19,20]. PDK1 is a ‘master kinase’ responsible
for activation loop phosphorylation of numerous AGC ki-
nases [2,21]. PDK1 phosphorylates PKB in vitro, and over-
expression of PDK1 in cells also leads to elevated Thr308
phosphorylation in the absence of natural agonists. PDK1
contains a C-terminal PH domain, and the rate of PKB phos-
phorylation by PDK1 is greatly enhanced in vitro by the
inclusion of PI(3,4,5)P3 or PI(3,4)P2, which concentrates
both upstream kinase and kinase substrate onto a lipid-micelle
surface [19]. In cells in which PDK1 has been genetically
disrupted, PKB is unresponsive to mitogenic stimulation as
a consequence of a loss of Thr308 phosphorylation [22]. Sim-
ilar results are observed with the disruption of PDK1 mRNA
[23].
A key di¡erence between the HM of PKB (and other AGC
kinases) compared with PKA is an additional layer of regu-
lation provided by HM phosphorylation. For PKBK, this tar-
get residue is Ser473. Phosphorylation of Ser473 increases the
a⁄nity of the HM for the PIF-pocket by several orders of
magnitude [12^14]. The mechanism of Ser473 phosphoryla-
Fig. 1. Regulation and targets of PKB/Akt. Ligation of receptor tyrosine kinases (RTKs) with their ligands (or through other agonist pathways
such as G protein-coupled receptors, not shown) leads to recruitment of members of the PI3K family of lipid kinases to the plasma membrane
where they encounter the substrate lipid phosphatidylinositol 4,5 bisphosphate (PIP2), leading to formation of 3,4,5 PIP3. This molecule re-
cruits PH domain containing proteins to the lipid bilayer including PKB and PDK1, where the former becomes activated (see also Fig. 2). Sub-
strates of PKB include transcription factors such as FKHR which regulates expression of Fas ligand and other molecules that promote apopto-
sis and metabolism. PKB phosphorylation of Bad, FKHR, p27Kip1 and GSK-3 inactivates these proteins, helping to suppress apoptosis and
promote glucose utilization.
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tion is not completely understood, and there is evidence sug-
gesting both autophosphorylation [24] and phosphorylation
by distinct serine kinases, including the integrin-linked kinase
(ILK; [25,26]). Furthermore, Hill and coworkers recently pu-
ri¢ed a Ser473 kinase activity isolated from buoyant lipid
rafts, distinct from both PDK1 and ILK [27].
4. Determinants of Thr308 and Ser473 phosphorylation
Several distinct criteria and inputs are required to trigger
Ser473 phosphorylation. Recent work with conditionally ac-
tive PKB models has assessed the requirements for Ser473
phosphorylation [28,29]. These studies revealed that plasma
membrane localization is a necessary criteria for Ser473 phos-
phorylation [29]. In cooperation with membrane location,
some catalytic activity of PKB is necessary for Ser473 phos-
phorylation, since kinase-dead forms (Lys179 to alanine mu-
tant) and Thr308 to alanine mutants are refractory. Inhibition
of PDK1 activity with staurosporine reduces the extent of
Thr308 phosphorylation, without a¡ecting Ser473 phosphor-
ylation, indicating that plasma membrane localization coop-
erates with basal PKB activity to activate Ser473 phosphory-
lation [29,30]. On the other hand, cytosolic PKB containing
an aspartic acid substitution at the Thr308 position is not
signi¢cantly phosphorylated at Ser473 [29]. It is di⁄cult to
interpret these observations to completely accommodate ei-
ther autophosphorylation or transphosphorylation by a dis-
tinct Ser473 kinase.
Complicating matters further, PI3K activity is required to
achieve Ser473 phosphorylation, in a manner distinct from the
actual membrane localization of PKB [28,29]. This could in-
dicate that PI3K-derived lipids activate a distinct Ser473 ki-
nase, inhibit a Ser473 phosphatase, or regulate the binding of
a Ser473-regulatory protein (such as CTMP; [31]). An inter-
esting possibility is that the phosphorylation of Thr308 pro-
motes a conformation of the PIF-pocket more suitable for
HM binding. The HM of PKB binds with much lower a⁄nity
to the PIF-pocket than the HM of other AGC kinases, such
as S6K and SGK, do to their own PIF-pockets [13]. There-
fore, small changes in the ternary structure of the kinase do-
main may in£uence the packing of the HM into the PIF-
pocket. Without Thr308 phosphorylation, the HM may be
more susceptible to phosphatases, leading to a net reduction
in phosphorylation. This possibility could have an impact on
the duration of PKB activity as it moves throughout the cell :
the phosphorylated and fully active form of PKB is stable,
allowing migration to the nucleus and other sites.
We recently showed in a study utilizing mast cells derived
from SHIP-knockout mice that the Ser473 activity was sensi-
tive to PI3K inhibition, even though under the conditions
tested phosphatidylinositol 3,4,5 trisphosphate (PIP3) levels
were high, PKB membrane localization was strong, and
Thr308 phosphorylation was normal [32]. In cells engineered
to lack SHIP, generation of mitogen-induced PIP3 is so ro-
bust that reduction of PI3K activity by 90% still leads to a
signi¢cant pool of PIP3, while completely abolishing
PI(3,4)P2. Adding back this lipid partially restores Ser473
phosphorylation and PKB activation. Thus, SHIP-derived
PI(3,4)P2 may serve a role in promoting and sustaining
Ser473 phosphorylation. This would be consistent with earlier
characterization of PKB showing that PI(3,4)P2 added to cells
could activate PKB e⁄ciently [33].
5. The HM and Ser473 bring PDK1 into the fold
A major goal for a number of research groups is under-
standing of the spatial and temporal constraints that limit
non-physiological phosphorylation of PKB by PDK1 and
the Ser473 kinase. This is particularly complex since PDK1
itself appears to be constitutively active, and the primary
means of its control is likely through PH-domain subcellular
targeting. For some substrates, PDK1-directed phosphoryla-
tion is constitutive, while for others, such as PKB, phosphor-
ylation is coupled to the activation of PI3K.
Biochemical and structure studies of PDK1 [12,34] and
PKB [14,5] provide important insight into this complex rela-
tionship. PDK1 harbors a hydrophobic and phosphate bind-
ing pocket similar to other AGC kinases, but lacks a comple-
mentary HM. In the absence of its own HM, PDK1
compensates by utilizing the HM of its substrates. Thus, the
HM of AGC kinases provides PDK1 with a docking and
activation mechanism. For PKB, PDK1 interacts with the
Ser473-phosphorylated HM, bringing PDK1 into proximity
to Thr308 and by causing a stabilizing e¡ect on the N-lobe,
increases its speci¢c activity.
The scenario that arises from these criteria suggests the
following order of events in PKB activation (Fig. 2). First,
PI3K-generated lipids recruit PKB and PDK1 to the plasma
membrane. Autophosphorylation (perhaps increased by con-
formational changes induced by lipid binding of the PH do-
main), or a membrane-localized kinase, promotes PKB phos-
phorylation on Ser473. The now phosphorylated HM
promotes interaction with PDK1, via its PIF-pocket. PDK1,
now activated and in stable contact with PKB, phosphorylates
Thr308. The Ser473-phosphorylated HM now prefers intra-
molecular association with its own PIF-pocket, releasing
PDK1 and adopting a fully active state for PKB.
Arguing against this hypothetical mechanism, recent work
suggests that the HM of PKB is not critical for docking
PDK1 in vivo [13,35]. This is argued because addition of
PIF-tide, which inhibits the PDK1-dependent phosphoryla-
tion of other AGC kinases, including p70 S6 kinase and
SGK, does not prevent PKB phosphorylation by PDK1 in
vitro. This ¢nding suggests that competition for the PIF-pock-
et of PDK1 does not restrict PDK1^PKB interaction, which
may instead be facilitated by the PH domain of PKB. How-
ever, PKB and PDK1 are colocalized to PIP3-containing
vesicles, while vPH-PKB, p70 S6 kinase and SGK are not.
It is unclear what e¡ect concentrating both substrate and ki-
nase on the lipid surface would have on the IC50 of the PIF-
tide. Also, while it is notable that vPH-PKB is sensitive to
PIF-tide, behaving similarly to p70 S6 kinase and SGK, it is
very poorly phosphorylated by PDK1 [13]. This is consistent
with the ¢nding that the HM of PKB binds with lower a⁄nity
to PDK1 than to the HM of SGK or p70 S6 kinase [12].
Overall, we interpret these data as indicating that phosphor-
ylation of Ser473, in the cytosol, is insu⁄cient to dock PDK1
and achieve Thr308 phosphorylation. Rather, both kinases
must be stably colocalized on lipid membranes to drive
PDK1-dependent phosphorylation. In support of this view,
we have shown that conditionally active PKB proteins, with
and without PH domains, require both Ser473 phosphoryla-
tion and membrane anchoring to achieve full Thr308 phos-
phorylation [29]. This is evidenced by the observation that
cytoplasmic vPH-PKB S473D mutants of PKB are much
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less sensitive to PDK1 phosphorylation than their equivalent
membrane-localized form.
6. PKB and tyrosine phosphorylation
Several recent reports have investigated the possible role of
tyrosine phosphorylation in PKB regulation [36^38]. One re-
port indicated that two tyrosine residues located within the
catalytic domain of PKB, Tyr315 and Tyr326, are phosphor-
ylated following receptor activation and are required for ac-
tivity, since mutation to phenylalanine abolished kinase activ-
ity [36]. However in the absence of either mass spectrometry
analysis or phosphopeptide mapping it is not clear that these
are true sites of tyrosine phosphorylation (see below). Also,
these residues are highly conserved in protein kinases, which
might suggest that their mutation to phenylalanine could im-
pact the structure and activity of the kinase domain indepen-
dently of phosphorylation.
A second report identi¢ed Tyr474, based on phosphopep-
tide mapping, as a possible site of phosphorylation in re-
sponse to insulin and pervanadate [38]. Mutation of this res-
idue to phenyalanine reduced Thr308 phosphorylation and
reduced PKB activation by about 55%. The crystal structure
of PKB indicates that Tyr474 participates in the binding of
the HM with the PIF-pocket: the aromatic ring of Tyr474
interacts with Leu214, while the hydroxyl group forms a hy-
drogen bond with Arg207 [5]. Thus, it is not necessarily sur-
prising that the mutation of Phe474 would result in reduced
activity, due to a loss of pHM-PIF-pocket a⁄nity. This might
also extend to a reduced ability of PDK1 to dock with and
phosphorylate PKB. A very interesting point is that the au-
thors show that Ser473 and Tyr474 phosphorylation are mu-
tually exclusive: phosphoamino acid analysis and N-terminal
sequencing of the tryptic peptide containing Ser473 and
Tyr474 show that neither are phosphorylated together. This
could indicate that phosphoTyr474 blocks the action of a
Ser473 kinase, or, by preventing the HM from packing into
the PIF-pocket might increase the susceptibility of Ser473 to
the actions of phosphatases. Based on these observations, it
might be considered that phosphorylation of Tyr474 repre-
sents an inhibitory input designed to limit the extent of
PKB activation. This tyrosine is conserved widely in the
AGC family, suggesting that a possible mechanism of regula-
tion could be a general feature. Further experiments are
needed to evaluate the role of Tyr474 in PKB regulation. In-
deed, since phospho-Ser473 antibodies are widely used to
monitor the activation state of PKB, it will be important to
assess whether the epitope detected by these antibodies is af-
fected by phosphorylation of Tyr474.
7. Conclusions
Clearly, PKB activation is complex, exhibiting a series of
spatial restrictions that limit phosphorylation by upstream
activators (Fig. 2). A principle component of PKB activation
is the generation of PIP3 and PI(3,4)P2 by PI3K. This is
necessary to localize PKB to membrane surfaces, where
Ser473 phosphorylation then occurs. The sustained phosphor-
ylation of Ser473 is also dependent on PI3K, through a pro-
cess that is distinct from membrane localization. This might
indicate that a Ser473 kinase, phosphatase or binding partner
is also in£uenced by PI3K. PDK1 associates with the Ser473-
Fig. 2. Activation Cycle of PKB/Akt. A: PKB is cytosolic and inactive. PDK1 has low activity, and Thr308 phosphorylation is not favorable.
B: PI3K-generated PIP3 And PI(3,4)P2 recruit PKB and PDK1 to the plasma membrane. PKB undergoes HM phosphorylation by the Ser473
kinase or by autophosphorylation. C: The HM of PKB stabilizes and activates PDK1, which then phosphorylates PKB on Thr308. D: The
HM of PKB associates with and stabilizes its kinase domain. The fully active kinase phosphorylates cytosolic and nuclear targets (Fig. 1). HM,
hydrophobic motif ; PH, pleckstrin homology domain; KD, kinase domain. Red circles indicate phosphorylation events.
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phosphorylated HM of PKB, which likely activates PDK1
su⁄ciently to catalyze phosphorylation of Thr308 of PKB.
The a⁄nity for the phosphorylated HM of PKB for PDK1
is less than the HM of other AGC kinases, including p70 S6
kinase and SGK. Thus, strict dependencies for membrane
localization to both fully promote Ser473 phosphorylation,
and to increase the relative concentration of kinase to sub-
strate are likely in place to prevent inappropriate PDK1 acti-
vation of PKB. Finally, the Ser473-phosphorylated HM then
plays a second major role, in which it binds with the PIF-
pocket of PKB generating a fully active, multiphosphorylated
PKB enzyme. In this stable form, PKB dissociates from the
plasma membrane and target substrates located in the cyto-
plasm and nucleus.
Remaining questions include the rationale for the complex-
ity of the activation process. Is it a re£ection of speci¢city,
allowing selective members of the AGC family to adapt to
activation by distinct agonist pathways? Is there a temporal
constraint to the process, such that the activation events are
ordered? Is the processing and activation of PKB a trigger for
other AGC kinase activations? Are there points of interven-
tion which act as gateways for regulation by other pathways?
There are likely many more surprises and confounding ele-
ments to this molecular machine. For example, PKB is trimer-
ized by binding to Tcl proteins [39,40], introducing yet more
possibilities for intramolecular control. The function of
CTMP in the process is also a conundrum [31]. Given the
importance of this protein kinase in a variety of human dis-
eases including cancer, diabetes and in£ammatory disease,
understanding of the precise molecular switches that must
be £ipped to achieve activation should lead to design of an-
tagonists that are selective for this process.
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